<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611948</url>
  </required_header>
  <id_info>
    <org_study_id>DA030988</org_study_id>
    <secondary_id>5R01DA030988-05</secondary_id>
    <nct_id>NCT01611948</nct_id>
  </id_info>
  <brief_title>Treatment for Cannabis Withdrawal and Dependence</brief_title>
  <official_title>Pharmacological Treatment of Cannabis Withdrawal and Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabis is the most widely used illicit drug in the United States, and worldwide, with 1 in
      10 users estimated to meet diagnostic criteria for cannabis dependence. Avoidance of
      withdrawal symptoms (e.g., disturbances in mood, sleep, and craving) is a common relapse
      precipitant. Cannabis use also impairs executive cognitive functions thereby increasing
      vulnerability to relapse and reducing the ability to benefit from behavioral therapy. There
      are no pharmacological treatments for cannabis dependence, despite the large number of
      afflicted individuals and the limitations of behavioral therapies which do not remediate
      withdrawal and are associated with high rates of treatment failure. The primary aim of this
      clinical trial is to evaluate the efficacy and safety of a novel neurokinin1 (NK1) receptor
      antagonist, aprepitant (Emend), (125mg/day), in outpatients with current cannabis dependence.
      The main hypothesis to be tested is to evaluate the relative efficacy of aprepitant 125 mg/d
      vs. placebo for reducing cannabis withdrawal symptoms in cannabis dependent outpatients,
      specifically anxiety, mood, craving and sleep.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase II, single-site, 8-week, randomized, double-blind,
      placebo-controlled, parallel group comparison of aprepitant (125 mg/d) or placebo. Subjects
      will be 100 outpatients seeking treatment for current cannabis dependence with no clinically
      significant medical or psychiatric disorders (including substance use disorders or a positive
      drug screen for substances other than cannabis or nicotine). All subjects will receive weekly
      manual-guided abstinence-oriented counseling to facilitate showing a drug effect above and
      beyond available therapies (Weeks 0-8). Research assessments of marijuana use and withdrawal
      and drug safety and tolerability will occur weekly through the treatment phase of the 8-week
      study. Post treatment follow-up assessments will occur at Weeks 9 and 12. Neuropsychological
      testing will occur at Weeks 0 and 4 and 8.

      Specific Aim 1: To evaluate the relative efficacy of aprepitant 125 mg/d vs. placebo for
      reducing cannabis withdrawal symptoms in cannabis dependent outpatients, including anxiety,
      mood, craving and sleep symptoms.

      Specific Aim 2: To evaluate the relative efficacy of aprepitant 125 mg/d vs. placebo for
      reducing marijuana use in cannabis dependent outpatients.

      Specific Aim 3: To evaluate the relative efficacy of aprepitant 125 mg/d vs. placebo for
      reducing cannabis related impairments in executive functioning in cannabis dependent
      outpatients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use. Change = (Week 8 value - Week 0 value).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>125mg/day for 8 weeks</description>
    <arm_group_label>Active Drug</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>125mg/d placebo pill for 8 weeks</description>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Manual-guided behavioral counseling</intervention_name>
    <description>Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.</description>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_label>Placebo pill</arm_group_label>
    <other_name>Manual-guided therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females from 18-70 years of age

          -  Meets DSM IV criteria for current cannabis dependence

          -  Seeking research-based outpatient treatment for cannabis dependence that involves
             daily oral medication

          -  Smoked MJ daily at least 25 days per month during the 90 days prior to randomization

          -  Current cannabis use verified by a positive urine test &gt; 50 ng/ml

          -  At least a 2-year history of regular MJ use

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Abstinent from cannabis more than 2 days at the time of randomization

          -  Currently meets DSM IV criteria for dependence on substances, or has urine drug screen
             positive for substances, other than cannabis or nicotine

          -  Meets DSM IV criteria for a major AXIS I disorder other than cannabis and nicotine
             dependence,

          -  Active suicidal ideation

          -  Significant medical disorders that will increase potential risk or interfere with
             study participation,

          -  Females who are pregnant, nursing or who are sexually active with child-bearing
             potential and refuse to use a double-barrier method of birth control during the study
             and for up to 4 weeks after study termination

          -  Ongoing treatment with medications that may affect study outcomes,

          -  Use of CYP3A4 strong inhibitors (e.g., ketoconazole, itraconazole, nefazodone,
             troleandomycin, clarithromycin, ritonavir, nelfinavir) and CYP3A4 moderate inhibitors
             (e.g., diltiazem) within the 2 week period prior the study drug administration or
             within 5 half-lives of the respective medication, whichever is longer, until study
             conclusion.

          -  Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study
             drug administration until study conclusion.

          -  Ongoing treatment with medications that are primarily metabolized by CYP3A4 and may
             have increased plasma concentrations when co-administered with aprepitant, such as
             pimozide, terfenadine, astemizole or cisapride or corticosteroids, as well as
             benzodiazepines including midazolam, alprazolam, and triazolam.

          -  Ongoing treatment with medications that are primarily metabolized by CYP2C9 (e.g.,
             warfarin, tolbutamide).

          -  Use of drugs (e.g., rifampin, carbamazepine, phenytoin) or herbal supplements (e.g.,
             St John's wort) that induce CYP3A4 activity and may result in reduced plasma
             concentrations of aprepitant and decreased efficacy of aprepitant.

          -  Inability to understand and/or comply with the provisions of the protocol and consent
             form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J Mason, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Scripps Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alcoholismmarijuanatreatment.com</url>
    <description>Study-related information</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <results_first_submitted>February 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Barbara J. Mason</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aprepitant: 125mg/Day</title>
          <description>125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
        <group group_id="P2">
          <title>Matched Placebo</title>
          <description>Matched Placebo daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aprepitant: 125mg/Day</title>
          <description>125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
        <group group_id="B2">
          <title>Matched Placebo</title>
          <description>Matched Placebo daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.09" spread="10.62"/>
                    <measurement group_id="B2" value="30.50" spread="12.19"/>
                    <measurement group_id="B3" value="31.69" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8</title>
        <description>Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use. Change = (Week 8 value - Week 0 value).</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <population>Two participants in the matched placebo arm who completed the double blind portion of the trial were unable to be analyzed for change in Urinary CN-THCCOOH Level due to missing data at Week 0 and/or Week 8. One sample was missing source documentation while the other sample was too dilute to return a reliable measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant: 125mg/Day</title>
            <description>125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo</title>
            <description>Matched Placebo daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8</title>
          <description>Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use. Change = (Week 8 value - Week 0 value).</description>
          <population>Two participants in the matched placebo arm who completed the double blind portion of the trial were unable to be analyzed for change in Urinary CN-THCCOOH Level due to missing data at Week 0 and/or Week 8. One sample was missing source documentation while the other sample was too dilute to return a reliable measurement.</population>
          <units>ng/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-334.21" spread="718.83"/>
                    <measurement group_id="O2" value="-359.95" spread="1207.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aprepitant: 125mg/Day</title>
          <description>125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
        <group group_id="E2">
          <title>Matched Placebo</title>
          <description>Matched Placebo daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Consipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barbara Mason</name_or_title>
      <organization>The Scripps Research Institute</organization>
      <phone>(858) 784-7324</phone>
      <email>mason@scripps.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

